| Stephanie Ann Adams, DO | |
|
1 Medical Park Blvd Ste 3w, Bristol, TN 37620-7430 | |
| (423) 282-1480 | |
| (423) 928-1353 |
| Full Name | Stephanie Ann Adams |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 18 Years |
| Location | 1 Medical Park Blvd Ste 3w, Bristol, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023289493 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 2097 (Tennessee) | Secondary |
| 207Q00000X | Family Medicine | 2097 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johnson City Medical Center | Johnson city, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Blue Ridge Medical Management Corporation | 9739099441 | 308 |
News Archive
The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.
Some low birth weight infants have large particles rich in apolipoprotein C-1, a blood protein that could put them at risk for heart disease later in life, according to a national study led by Johns Hopkins Children's Center researchers.
Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.
German researchers working with stem cell therapy have claimed they have cured an American patient with HIV and leukemia. Experts are wary of accepting the development at its face value and caution that there is a need for further research. Dr David Scadden, a co-director of the Harvard University Stem Cell Institute added, "Cured is a strong word. But this is very encouraging… from all indications, there was no residual virus… It's as good an outcome as one could hope for."
› Verified 2 days ago
| Entity Name | Blue Ridge Medical Management Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144380833 PECOS PAC ID: 9739099441 Enrollment ID: O20031204000996 |
News Archive
The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.
Some low birth weight infants have large particles rich in apolipoprotein C-1, a blood protein that could put them at risk for heart disease later in life, according to a national study led by Johns Hopkins Children's Center researchers.
Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.
German researchers working with stem cell therapy have claimed they have cured an American patient with HIV and leukemia. Experts are wary of accepting the development at its face value and caution that there is a need for further research. Dr David Scadden, a co-director of the Harvard University Stem Cell Institute added, "Cured is a strong word. But this is very encouraging… from all indications, there was no residual virus… It's as good an outcome as one could hope for."
› Verified 2 days ago
| Entity Name | Southeastern Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083835441 PECOS PAC ID: 0042307852 Enrollment ID: O20071025000571 |
News Archive
The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.
Some low birth weight infants have large particles rich in apolipoprotein C-1, a blood protein that could put them at risk for heart disease later in life, according to a national study led by Johns Hopkins Children's Center researchers.
Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.
German researchers working with stem cell therapy have claimed they have cured an American patient with HIV and leukemia. Experts are wary of accepting the development at its face value and caution that there is a need for further research. Dr David Scadden, a co-director of the Harvard University Stem Cell Institute added, "Cured is a strong word. But this is very encouraging… from all indications, there was no residual virus… It's as good an outcome as one could hope for."
› Verified 2 days ago
| Entity Name | Wellmont Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780986257 PECOS PAC ID: 8123291739 Enrollment ID: O20111026000909 |
News Archive
The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.
Some low birth weight infants have large particles rich in apolipoprotein C-1, a blood protein that could put them at risk for heart disease later in life, according to a national study led by Johns Hopkins Children's Center researchers.
Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.
German researchers working with stem cell therapy have claimed they have cured an American patient with HIV and leukemia. Experts are wary of accepting the development at its face value and caution that there is a need for further research. Dr David Scadden, a co-director of the Harvard University Stem Cell Institute added, "Cured is a strong word. But this is very encouraging… from all indications, there was no residual virus… It's as good an outcome as one could hope for."
› Verified 2 days ago
| Entity Name | Ipc Pac Healthcare Services Of Tennessee Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104277656 PECOS PAC ID: 0840587572 Enrollment ID: O20160928000541 |
News Archive
The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.
Some low birth weight infants have large particles rich in apolipoprotein C-1, a blood protein that could put them at risk for heart disease later in life, according to a national study led by Johns Hopkins Children's Center researchers.
Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.
German researchers working with stem cell therapy have claimed they have cured an American patient with HIV and leukemia. Experts are wary of accepting the development at its face value and caution that there is a need for further research. Dr David Scadden, a co-director of the Harvard University Stem Cell Institute added, "Cured is a strong word. But this is very encouraging… from all indications, there was no residual virus… It's as good an outcome as one could hope for."
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephanie Ann Adams, DO 1021 W Oakland Ave Ste 310, Johnson City, TN 37604-2192 Ph: (423) 302-6565 | Stephanie Ann Adams, DO 1 Medical Park Blvd Ste 3w, Bristol, TN 37620-7430 Ph: (423) 282-1480 |
News Archive
The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.
Some low birth weight infants have large particles rich in apolipoprotein C-1, a blood protein that could put them at risk for heart disease later in life, according to a national study led by Johns Hopkins Children's Center researchers.
Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.
German researchers working with stem cell therapy have claimed they have cured an American patient with HIV and leukemia. Experts are wary of accepting the development at its face value and caution that there is a need for further research. Dr David Scadden, a co-director of the Harvard University Stem Cell Institute added, "Cured is a strong word. But this is very encouraging… from all indications, there was no residual virus… It's as good an outcome as one could hope for."
› Verified 2 days ago
Dr. Michael D. Thornsberry, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 220 Country Meadows Cir, Bristol, TN 37620 Phone: 423-914-6265 | |
Andrew Brockmyre, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 240 Medical Park Blvd, Ste 3600, Bristol, TN 37620 Phone: 423-990-2400 | |
Andrea Lynne Hopkins, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 208 Medical Park Blvd, Bristol, TN 37620 Phone: 423-989-4050 Fax: 423-990-3044 | |
Christopher Garner, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 208 Medical Park Blvd, Bristol, TN 37620 Phone: 423-989-4050 Fax: 423-990-3045 | |
Dr. J Scott Ries, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 504 Old Jonesboro Road, Bristol, TN 37620 Phone: 423-844-1000 | |
Frederick Mitchell Litton, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 237 Old Stage Drive, Bristol, TN 37620 Phone: 423-230-2420 Fax: 423-230-2422 | |
Frederick A Martin, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1958 W State St, Bristol, TN 37620 Phone: 423-574-7575 Fax: 423-574-7576 |